Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes
Endocrinology and Metabolism Clinics of North America · 2026-09 · 55 (3) · 537-546
DOI: 10.1016/j.ecl.2026.04.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2026-09. Verfasst von Jayachidambaram Ambalavanan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Maine Health Maine Medical Center and Tufts University School of Medicine, Scarborough, ME, USA. …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetic Ketoacidosis, Hypoglycemic Agents, Practice Guidelines as Topic. Die Arbeit nennt 49 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Sodium-glucose cotransporter inhibitors (SGLTi) as an adjunctive to insulin therapy may offer cardiometabolic and renal benefits in adults with type 1 diabetes (T1D). Their effective use depends on patient selection, education, and ketone monitoring to prevent diabetic ketoacidosis (DKA). Starting with the lowest effective dose, making appropriate insulin adjustments, and following structured protocols for ketone monitoring and DKA risk mitigation are essential for safe use of SGLTi in adults with T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, Maine Health Maine Medical Center and Tufts University School of Medicine, Scarborough, ME, USA. Electronic address: jay.ambalavanan@mainehealth.org.
- Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN, USA.
Zitieren
APA
Ambalavanan, J., Bhasin, K., & Shah, V. N. (2026). Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 55(3), 537-546. https://doi.org/10.1016/j.ecl.2026.04.013
Vancouver
Ambalavanan J, Bhasin K, Shah VN. Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America. 2026;55(3):537-546. doi:10.1016/j.ecl.2026.04.013
BibTeX
@article{Ambalavanan2026,
author = {Ambalavanan, Jayachidambaram and Bhasin, Kanchan and Shah, Viral N},
title = {Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes},
journal = {Endocrinology and Metabolism Clinics of North America},
year = {2026},
volume = {55},
number = {3},
pages = {537--546},
doi = {10.1016/j.ecl.2026.04.013}
}
EUVIMED